DBDavid Barros-Sierra

David Barros-Sierra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Barros-Sierra has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Seroprevalencia a SARSCoV- 2 en trabajadores de los sectores esencial (comercio) y no esencial (educativo) durante 2021 en México

    by Rodrigo Zepeda Tello, Juan Edgar García-Flores, Marcela Tamayo Ortiz, David Barros-Sierra, Mauricio Hernández-Ávila

  • Open Access

    The Omicron wave in Mexico: vaccine protection against progression to severe Covid-19 in SARS-CoV-2-infected workers

    by Mauricio Hernández-Ávila, Waldo Iván Vieyra-Romero, Héctor Osiris Gutiérrez-Díaz, Rodrigo Zepeda-Tello, Celia Alpuche-Aranda, Juan Eugenio Hernández-Ávila, David Barros-Sierra, Marcela Tamayo-Ortiz, Celida Duque-Molina, Tonatiuh Barrientos-Gutiérrez, et al.

    Objective. To assess the effectiveness of seven Covid-19 vaccines in preventing disease progression (DP) using data from national private sector workers during the Omicron wave in Mexico from January 2 to March 5, 2022. Materials and methods. This study employed an administrative retrospective cohort design, analyzing DP (hospitalization or death due to respiratory disease) among workers who filed a respiratory short-term disability claim and tested positive for SARS-CoV-2. Risk ratios (RRadj) were estimated using Poisson regression models adjusted for various factors. Results. Vaccinated individuals had a lower risk of hospitalization and death compared with unvaccinated individuals. The overall RRadj for hospitalization and death were 0.36 (95%CI 0.32, 0.41) and 0.24 (0.17, 0.33), respectively. When evaluating vaccines individually, the RRadj for hospitalization were as follows Pfizer BioNTech 0.27 (95%CI 0.22, 0.33), Moderna 0.29 (95%CI 0.15, 0.57), Sinovac 0.32 (95%CI 0.25, 0.41), AstraZeneca 0.39 (95%CI 0.34, 0.46), Sputnik 0.39 (95%CI 0.28, 0.53), CanSino 0.41 (95%CI 0.24, 0.7), and Janssen 0.53 (95%CI 0.39, 0.72). The RRadj for death were as follows: Pfizer BioNTech 0.12 (95%CI 0.07, 0.19), Sputnik 0.15 (95%CI 0.06, 0.38), Sinovac 0.29 (95%CI 0.16, 0.53), AstraZeneca 0.30 (95%CI 0.20, 0.44), CanSino 0.38 (95%CI 0.1, 1.4), and Janssen 0.50 (95%CI 0.26, 0.97). Conclusion. Covid-19 vaccines significantly reduced the risk of severe disease during the Omicron wave in Mexico.


  • Open Access

    SARS-CoV-2 seroprevalence and respiratory disease disability claims in Mexico City Metropolitan Area

    by David Barros-Sierra, Rodrigo Zepeda-Tello, Marcela Tamayo-Ortiz, Hector Osiris Gutiérrez-Díaz, Valeria Aurora Pérez-Chávez, José Antonio Rosa-Parra, Luis Enrique Nieto-Barajas, Mauricio Méndez-Aranda, Luis Alonso Herrera-Montalvo, Mauricio Hernández-Ávila

    Objective. To characterize the impact of SARS-CoV-2 infection in workers from an essential large-scale company in the Greater Mexico City Metropolitan Area using point prevalence of acute infection, point prevalence of past infection through serum antibodies and respiratory disease short-term disability claims (RD-STDC). Materials and methods. Four randomized surveys, three during 2020 before and one after (December 2021) vaccines' availability. Outcomes: point prevalence of acute infection through saliva PCR (polymerase chain reaction) testing, point prevalence of past infection through serum antibodies against Covid-19, RD-STDC and prevalence of symptoms during the previous six months. Results. Prevalence of SARS-CoV-2 cases was 1.29-4.88%, on average, a quarter of participants pre-vaccination were seropositive; over half of participants with a RD-STDC had antibodies. The odds of having antibodies were 6-7 times more among workers with an RD-STDC. Conclusions. High antibody levels against Covid-19 in this study population reflects that coverage is high among workers in this industry. STDCs are a useful tool to track workplace epidemics.